Robotic versus Open Radical Cystectomy: An Updated Systematic Review and Meta-Analysis

Leilei Xia*, Xianjin Wang*, Tianyuan Xu*, Xiaohua Zhang, Zhaowei Zhu, Liang Qin, Xiang Zhang, Chen Fang, Minguang Zhang, Shan Zhong, Zhoujun Shen*

Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P. R. China

* These authors contributed equally to this work.

Abstract

Objective
To critically review the currently available evidence of studies comparing robot-assisted radical cystectomy (RARC) with open radical cystectomy (ORC).

Methods
A comprehensive review of the literature from Pubmed, Web of Science and Scopus was performed in April 2014. All relevant studies comparing RARC with ORC were included for further screening. A pooled meta-analysis of all comparative studies was performed and publication bias was assessed by a funnel plot.

Results
Nineteen studies were included for the analysis, including a total of 1779 patients (787 patients in the RARC group and 992 patients in the ORC group). Although RARC was associated with longer operative time ($p < 0.0001$), patients in this group might benefit from significantly lower overall perioperative complication rates within 30 days and 90 days ($p = 0.005$ and 0.0002, respectively), more lymph node yields ($p = 0.009$), less estimated blood loss ($p < 0.00001$), lower need for perioperative and intraoperative transfusions ($p < 0.0001$ and $< 0.0001$, respectively), and shorter postoperative length of stay ($p = 0.0002$). There was no difference between two groups regarding positive surgical margin rates ($p = 0.19$).

Conclusions
RARC appears to be an efficient alternative to ORC with advantages of less perioperative complications, more lymph node yields, less estimated blood loss, lower need for transfusions, and shorter postoperative length of stay. Further studies should be performed to compare the long-term oncologic outcomes between RARC and ORC.
Introduction

Radical cystectomy (RC) and pelvic lymph node dissection (PLND) are the standard treatments for muscle invasive and high risk non-muscle invasive bladder cancer [1]. Open radical cystectomy (ORC) is a procedure that has been troubled with high rates of perioperative complication and mortality [2]. Minimally invasive surgeries, such as laparoscopic radical cystectomy (LRC) and robot-assisted radical cystectomy (RARC) have been applied increasingly with the goal of decreasing perioperative morbidity and mortality. Menon et al. [3] reported the first series of RARC in 2003 and demonstrated its safety and feasibility. Since then, especially in the latest 5 years, RARC has gained its popularity and achieved decent long-term oncologic outcomes [4,5]. As to comparative analysis of complication rates and perioperative outcomes between RARC and ORC, different studies showed controversial results [6–20]. In 2012, Li et al. [21] conducted a systematic review of literatures, with a meta-analysis of the results to compare RARC with ORC. The analysis of complication rates in their meta-analysis, however, were relatively sketchy because the authors did not take fully account of complication grades and postoperative period. Besides, some high-quality studies, including a randomized controlled trial (RCT), have been reported since 2012 [22–25]. Therefore, we performed an updated meta-analysis of literatures comparing complication rates and perioperative outcomes of RARC with those of ORC.

Methods

Search strategy and study selection

A literature search was performed in the electronic databases of PubMed, Web of Science, and Scopus. Language was restricted to English. The following terms and their combinations were searched in [Title/Abstract]: cystectomy, bladder resection, robotic, robot, robot-assisted, and da Vinci. The last updated search was performed on April 10, 2014. Article selection proceeded according to the search strategy based on Preferred Reporting Items for Systematic Reviews and Meta-analysis criteria [26]. Cited references from the selected articles were manually searched and assessed. The following inclusion criteria were used: (i) studies comparing RARC with ORC; (ii) at least one of the quantitative outcomes were included; and (iii) RCT, prospective or retrospective comparative study design. Review articles, case reports, editorials, comments, letters to the editor, and conference abstracts were excluded.

Data extraction and outcomes of interest

Two reviewers (X. W. and T. X.) independently extracted and summarized the following data from the included studies: authors, publication year, country, study design, matching factors (age, gender, body mass index, American Society of Anesthesiologists score, diversion type, clinical stage, Charlson index, neoadjuvant chemotherapy, previous abdominal/pelvic radiotherapy, previous pelvic/abdominal surgery, and numbers of surgeon), and outcomes of interest. The outcomes of interest were perioperative complication rates within 30 days or 90 days of the date of surgery and other perioperative outcomes. Complications were classified into grade 1, 2, 3, 4, and 5 according to the Clavien-Dindo grading system [27]. Other perioperative outcomes were positive surgical margin (PSM; including urethral/ureteric and soft tissue PSM) rates, lymph node yields (LNY), operative time (OT), estimated blood loss (EBL), transfusion (including perioperative and intraoperative transfusion) rates, and postoperative length of stay (LOS). Any disagreements were resolved by discussion until a consensus was reached.
Study quality assessment

The level of evidence (LOE) of included studies was rated according to the criteria provided by the Oxford Center for Evidence-Based Medicine [28]. The methodological quality of the studies was assessed using Newcastle-Ottawa Scale (NOS) for observational comparative studies [29] and Jadad scale for randomized controlled trials (RCTs) [30,31]. The NOS evaluates the quality of studies by examining three aspects of the study design: patient selection, comparability of the study groups, and assessment of outcomes. A score of 0 to 9 may be given to individual studies. Studies achieving a score of 7 or more indicate a high quality. Jadad scale is a 5-point scale and a score of 2 or less indicates low quality while 3 or more high quality. Two reviewers (X. W. and T. X.) independently assessed the quality of the studies and disagreement was resolved by consensus.

Statistical analysis

The meta-analyses were performed using Review Manager Version 5.2 (The Cochrane Collaboration, Software Update, Oxford). The weighted mean difference (WMD) and odds ratios (ORs) were used to compare continuous and dichotomous variables, respectively. All results were reported with 95% confidence intervals (CIs). For studies presenting continuous data as median and range or interquartile range, the means and standard deviations (SDs) were calculated using the methodology described by Hozo et al. [32] in keeping with Cochrane handbook [33]. Statistical heterogeneity between studies was assessed using the chi-squared ($\chi^2$) test with a P value of $<0.1$ considered to indicate statistical significance, and heterogeneity was quantified using the inconsistency ($I^2$) statistic. A random-effect model was used for outcomes that displayed significant heterogeneity with $I^2$ values $>50$%; otherwise, the fixed-effect model was used. To evaluate the difference in results from studies with surgeon have greater experience in RARC, subgroup analysis of studies with more than 50 RARC cases was also performed. The outcomes of subgroup analysis include overall complication rates within 30 days and 90 days, PSM rates, LNY, OT, EBL, and LOS. Publication bias was assessed by a funnel plot.

Results

Characteristics and methodological quality of included studies

The literature search yielded 585 studies, of which 19 were selected in the final analysis including 1779 cases (787 cases for RARC and 992 cases for ORC) (Fig 1) [6–19,22–25]. Three [6,9,12] and another three [8,10,25] publications shared overlapping populations but had some different outcomes. The characteristics of included studies are summarized in Table 1. As for urinary diversion, sixteen adopted the extracorporeal method [6,7,9–17,20,22–25]. Similar neobladders were reconstructed between RARC and ORC groups (131 of 593 vs 125 of 654 in thirteen studies [6,7,9–14,16,17,23–25] (p = 0.08).

There were two RCTs comparing the two procedures [11,22] (evidence level: 2b). Ten observational studies declared prospective data collection [6,8–10,13–15,18,19,23] and seven were retrospective studies [7,12,16,17,20,24,25]. All observational comparative studies had evidence level 3. Thirteen of them had a score of $\geq 7$ and were considered high quality.

Meta-Analysis Results

1. Complications. Pooled data of five studies that assessed overall perioperative complications within 30 days in 575 patients showed significantly lower complication rate in the RARC group (OR: 0.61; 95% CI, 0.44–0.86; p = 0.005) (Table 2 and Fig 2). Overall perioperative complications within 90 days were available in 761 patients from other five studies, the pooled
analysis of which also showed significantly lower complication rate in the RARC group (OR: 0.32; 95% CI, 0.17–0.57; p = 0.0002) (Table 2 and Fig 2).

Overall perioperative complications were further divided into grade 1 to 5 in studies with detailed data. Within 30 days, there was no significant difference in grade 1, 2 and 3 complication rates between two groups (p = 0.13, 0.23, and 0.40, respectively), but significantly lower grade 4 complication rate were observed in the RARC group (p = 0.04) (Table 2 and Fig 3). Within 90 days, there was no significant difference in grade 1 and 2 complication rates (p = 0.83 and 0.10, respectively), but grade 3 and 4 complication rates were significantly lower in the RARC group (p = 0.001 and 0.004, respectively) (Table 2 and Fig 4). Perioperative mortality (grade 5 complication) rates within 30 days and 90 days were similar between the two groups (p = 0.55 and 0.23, respectively) (Table 2, Fig 3 and Fig 4).
2. PSM and LNY.  Pooled data of nine studies that assessed overall PSM rates in 918 patients showed no significant difference between RARC and ORC groups (p = 0.19) (Table 3 and Fig 5). Urethral/ureteric and soft tissue PSM rates were assessed in three studies, and there was no significant differences between the two groups (p = 0.51 and 0.38, respectively) (Table 3 and Fig 5). Pooling data of thirteen studies that counted LNY in 1500 patients showed significantly more LNY in RARC than the ORC group (WMD: 2.98; 95% CI, 0.74–5.22; p = 0.009) (Table 3 and Fig 6).

Table 1. Characteristics of the included studies and quality assessment.

| First author, year of publication | Country | Study design | LOE Quality Scores | No. of patients | Urinary diversion method | No. of neobladder | Matching# |
|----------------------------------|---------|--------------|--------------------|-----------------|-------------------------|------------------|-----------|
| Galich 2006 [6]                 | USA     | Prospective  | 3 6 of 9           | 13 24           | Extracorporeal          | 5 7              | 1 2 3 5 6 11 |
| Pruthi 2007 [7]                 | USA     | Retrospective| 3 7 of 9           | 20 24           | Extracorporeal          | 10 5             | 2 5 6 11  |
| Sterrett 2007 [8]               | USA     | Prospective  | 3 7 of 9           | 19 33           | Unclear                 | NA NA            | 1 2 3    |
| Wang 2008 [9]                   | USA     | Prospective  | 3 7 of 9           | 33 21           | Extracorporeal          | 12 5             | 1 3 4 5 6 9 10 11 |
| Ng 2010 [10]                    | USA     | Prospective  | 3 6 of 9           | 83 104          | Extracorporeal          | 26 29            | 2 3 4 5 6 7 11 |
| Nix 2010 [11]                   | USA     | RCT          | 2b 2 of 5 points   | 21 20           | Extracorporeal          | 7 6              | 1 2 3 4 5 6 |
| Richards 2010 [12]             | USA     | Retrospective| 3 7 of 9           | 35 35           | Extracorporeal          | 3 4              | 1 2 3 4 5 6 8 9 10 |
| Martin 2011 [18]                | USA     | Prospective  | 3 6 of 9           | 19 14           | Unclear                 | NA NA            | 1 2 3 4    |
| Abaza 2012 [19]                 | USA     | Prospective  | 3 7 of 9           | 35 120          | Unclear                 | NA NA            | 1 5 6 8    |
| Gondo 2012 [13]                 | Japan   | Prospective  | 3 6 of 9           | 11 15           | Extracorporeal          | 4 6              | 1 2 3 5 7 8 9 10 11 |
| Khan 2012 [14]                  | UK      | Prospective  | 3 7 of 9           | 48 52           | Extracorporeal          | 6 5              | 1 2 4 5    |
| Styn 2012 [15]                  | USA     | Prospective  | 3 7 of 9           | 50 100          | Extracorporeal          | NA NA            | 1 2 3 4 5 6 7 8 9 10 |
| Sung 2012 [16]                  | Korea   | Retrospective| 3 7 of 9           | 35 104          | Extracorporeal          | 22 19            | 1 2 3 4 6 7 8 9 10 |
| Kader 2013 [25]                 | USA     | Retrospective| 3 7 of 9           | 100 100         | Extracorporeal          | 3 12             | 1 2 3 4 5 8 10 |
| Knox 2013 [24]                  | USA     | Retrospective| 3 7 of 9           | 58 84           | Extracorporeal          | 5 9              | 1 2 3 4 5 6 8 9 10 |
| Musch 2013 [23]                 | Germany | Prospective  | 3 7 of 9           | 100 42          | Extracorporeal          | 22 7             | 1 2 3 4 6 7 |
| Nepple 2013 [17]                | USA     | Retrospective| 3 7 of 9           | 36 29           | Extracorporeal          | 6 11             | 3 5 6 8 11 |
| Parekh 2013 [22]                | USA     | RCT          | 2b 2 of 5 points   | 20 20           | Extracorporeal          | NA NA            | 1 2 3 4 6 8 10 11 |
| Ahdoot 2014 [20]                | USA     | Retrospective| 3 7 of 9           | 51 51           | Extracorporeal          | NA NA            | Propensity adjusted |

RARC = robot-assisted radical cystectomy; ORC = open radical cystectomy; LOE: level of evidence; RCT = randomized controlled trial; NA = data not available.

*Using Newcastle-Ottawa Scale (NOS) for observational comparative studies and Jadad scale for RCTs.

#Matching: 1 = age; 2 = gender; 3 = body mass index; 4 = American Society of Anesthesiology score; 5 = diversion type; 6 = clinical stage; 7 = Charlson index; 8 = neoadjuvant chemotherapy; 9 = previous abdominal/pelvic radiotherapy; 10 = previous abdominal/pelvic surgery; 11 = numbers of surgeon.

3. OT, EBL, transfusion and LOS.  Pooled data of nine studies including 1047 patients showed significantly longer OT in the RARC than the ORC group (WMD: 73.92; 95% CI, 37.18–110.67; p < 0.0001) (Table 3 and Fig 7). Pooled data of ten studies including 1189 patients that evaluated EBL showed significantly lower blood loss in the RARC than the ORC group (WMD: -47.39; 95% CI, -65.13 –29.65; p < 0.00001) (Table 3 and Fig 8). Pooled data of seven studies including 826 patients that evaluated perioperative transfusion rates showed
significantly lower rate in the RARC than the ORC group (p < 0.0001) (Table 3 and Fig 9). Pooled data of three studies including 241 patients that evaluated intraoperative transfusion rates showed significantly lower rate in the RARC than the ORC group (p < 0.0001) (Table 3 and Fig 9). Pooled data of ten studies including 1247 patients that evaluated LOS showed significantly shorter LOS in the RARC group (WMD: -3.16; 95% CI, -4.84–1.48; p < 0.0001) (Table 3 and Fig 10).

RARC = robot-assisted radical cystectomy; ORC = open radical cystectomy; OR = odds ratio; WMD = weighted mean difference; CI = confidence interval.

* Statistically significant results are shown in bold.

doi:10.1371/journal.pone.0121032.t002

### Table 2. Complication rates comparing robot-assisted radical cystectomy with open radical cystectomy.

| Complication rates | No. of studies [reference] | No. of patients | RARC/ORC | OR 95% CI | P value* | Study heterogeneity |
|--------------------|----------------------------|-----------------|----------|-----------|----------|---------------------|
| Overall within 30 d| 5 [10,12,13,15,24]         | 237/338         | 0.61     | 0.44, 0.86| 0.005    | 5.48 4 27 0.24 |
| Grade 1 within 30 d| 4 [10,12,13,24]            | 187/228         | 0.66     | 0.39, 1.13| 0.13     | 2.36 3 0 0.50 |
| Grade 2 within 30 d| 4 [10,12,13,24]            | 187/228         | 0.45     | 0.12, 1.65| 0.23     | 20.97 3 86 0.0001|
| Grade 3 within 30 d| 4 [10,12,13,24]            | 187/228         | 0.61     | 0.20, 1.92| 0.40     | 9.82 3 69 0.02 |
| Grade 4 within 30 d| 4 [10,12,13,24]            | 187/228         | 0.34     | 0.12, 0.95| 0.04     | 1.10 2 0 0.58 |
| Grade 5 within 30 d| 4 [10,12,13,24]            | 187/228         | 0.46     | 0.12, 1.76| 0.25     | 2.42 2 17 0.30 |
| Overall within 90 d| 5 [10,14,16,23,25]         | 358/403         | 0.32     | 0.17, 0.67| 0.0002   | 10.84 4 63 0.03 |
| Grade 1 within 90 d| 3 [10,16,25]              | 218/308         | 0.81     | 0.12, 5.63| 0.83     | 17.05 2 88 0.0002|
| Grade 2 within 90 d| 3 [10,16,25]              | 218/308         | 0.31     | 0.08, 1.25| 0.10     | 21.16 2 91 <0.0001|
| Grade 3 within 90 d| 3 [10,16,25]              | 218/308         | 0.42     | 0.25, 0.70| 0.001    | 0.31 2 0 0.86 |
| Grade 4 within 90 d| 3 [10,16,25]              | 218/308         | 0.22     | 0.08, 0.62| 0.004    | 0.24 2 0 0.89 |
| Grade 5 within 90 d| 3 [10,16,25]              | 218/308         | 0.45     | 0.12, 1.66| 0.23     | 2.99 2 33 0.22 |

Fig 2. Forest plots of overall complication rates. (a) within 30 days; (b) within 90 days.

doi:10.1371/journal.pone.0121032.g002
4. Subgroup analysis. Five studies with more than 50 RARC cases were included for subgroup analysis [10,20,23–25] (Fig 11). It continued to demonstrate lower overall complication rates within 30 days (WMD: 0.46; 95% CI, 0.29–0.72; p = 0.0006) and 90 days (WMD: 0.34; 95% CI, 0.18–0.66; p = 0.001) in RARC group. No significant difference in PSM rates between two groups was observed (WMD: 0.94; 95% CI, 0.52–1.36; p = 0.82). More LNY (WMD: 5.47; 95% CI, 1.68–9.26; p = 0.005), longer OT (WMD: 46.85; 95% CI, 22.60–71.09; p = 0.0002), less...
EBL (WMD: -60.85; 95% CI, -77.28 to -44.42; p < 0.00001), and shorter LOS (WMD: -3.05; 95% CI, -4.70 to -1.39; p = 0.0003) were observed in the RARC group.

5. Publication bias. Fig 12 shows funnel plots of the studies included in this meta-analysis reporting perioperative complication rates within 30 days. All studies lie inside the 95% CIs, with an even distribution around the vertical, indicating no obvious publication bias.
Currently, RARC are being increasingly adopted for the treatment of muscle invasive and high-risk non-muscle invasive bladder cancer. Li et al. [21] conducted a systematic review and meta-analysis in 2012, with the goal of comparing RARC with ORC in terms of perioperative surgical and oncologic outcomes. However, in that study, the authors did not take fully account of the complication grades and postoperative period. Besides, some high-quality studies comparing RARC with ORC have been reported since 2012. We thus performed an updated systemic review and meta-analysis. In this review, nineteen studies, including two RCTs, ten prospective and seven retrospective studies, were included. Pooled data indicated significantly lower overall perioperative complication rates within 30 days and 90 days, more LNY, longer OT, less EBL, lower perioperative and intraoperative transfusion rates, and shorter LOS in the RARC than the ORC group.

RC is a highly challenging operation with relatively high risk of perioperative morbidity and mortality. Accordingly, perioperative complication rate is an important evaluation indicator for this procedure. As the reporting methods of complications were various and nonstandardized among the included studies, especially the postoperative period, we thus pooled data of complication rates within 30 days and 90 days postoperatively. Moreover, we also analyzed the complication rates using the Clavien grading system. Overall perioperative complication rates within 30 days and 90 days were significantly lower in the RARC group than the ORC group. After grading complications, grade 4 complication rate was significantly lower in the RARC group within 30 days, and grade 3–4 complication rates were significantly lower in the RARC group within 90 days. The results indicates that RARC might be safer compared to ORC, especially in the long term. Of all the included studies, Ng et al. [10] reported their complications using a more standard method with detailed data. Their results showed that RARC was an independent predictor of fewer overall and major complications within 30 days and 90 days postoperatively, and higher

### Table 3. Perioperative outcomes comparing robot-assisted radical cystectomy with open radical cystectomy.

| Outcomes                        | No. of studies [references] | No. of patients RARC/ORC | OR/WMD† | 95% CI       | P value* | Study heterogeneity |
|---------------------------------|------------------------------|--------------------------|---------|--------------|----------|---------------------|
| PSM rates                       | 9 [6,7,10,13,14,22–25]      | 453/465                  | 0.71    | 0.43, 1.18   | 0.19     | 4.00 8 0 0.86       |
| Ureteric/urethral PSM           | 3 [15,17,20]                | 137/180                  | 1.32    | 0.58, 3.02   | 0.51     | 0.12 2 0 0.94       |
| Soft tissue PSM                 | 3 [15,17,20]                | 137/180                  | 0.56    | 0.15, 2.08   | 0.38     | 1.81 2 0 0.41       |
| LNY                             | 13 [7,10,11,14–20,23–25]    | 656/644                  | 2.98†   | 0.74, 5.22   | 0.009    | 78.95 12 85 <0.00001|
| OT, min                         | 9 [7,8,10,14–16,18,23,25]   | 474/573                  | 73.92†  | 37.18, 110.67| <0.0001  | 91.08 8 91 <0.00001 |
| EBL, 10 ml                      | 10 [7,8,10,14–16,18,23–25]  | 532/657                  | -47.39† | -65.13, -29.65| <0.00001 | 72.37 9 88 <0.00001 |
| Perioperative transfusion       | 7 [8,14,15,22–25]           | 395/431                  | 0.14    | 0.06, 0.36   | <0.0001  | 30.04 6 80 <0.0001  |
| Intraoperative transfusion      | 3 [13,15,17]                | 97/144                   | 0.14    | 0.06, 0.34   | <0.0001  | 0.37 2 0 0.83       |
| LOS, d                          | 10 [8,10,14–16,18,20,23–25] | 563/684                  | -3.16†  | -4.84, -1.48 | 0.0002  | 41.90 9 79 <0.00001 |

RARC = robot-assisted radical cystectomy; ORC = open radical cystectomy; OR = odds ratio; WMD = weighted mean difference; CI = confidence interval; PSM = positive surgical margin; LNY = lymph node yields; OT = operative time; EBL = estimated blood loss; LOS = length of stay.

†WMD

* Statistically significant results are shown in bold

doi:10.1371/journal.pone.0121032.t003

### Discussion

Currently, RARC are being increasingly adopted for the treatment of muscle invasive and high-risk non-muscle invasive bladder cancer. Li et al. [21] conducted a systematic review and meta-analysis in 2012, with the goal of comparing RARC with ORC in terms of perioperative surgical and oncologic outcomes. However, in that study, the authors did not take fully account of the complication grades and postoperative period. Besides, some high-quality studies comparing RARC with ORC have been reported since 2012. We thus performed an updated systemic review and meta-analysis. In this review, nineteen studies, including two RCTs, ten prospective and seven retrospective studies, were included. Pooled data indicated significantly lower overall perioperative complication rates within 30 days and 90 days, more LNY, longer OT, less EBL, lower perioperative and intraoperative transfusion rates, and shorter LOS in the RARC than the ORC group.

RC is a highly challenging operation with relatively high risk of perioperative morbidity and mortality. Accordingly, perioperative complication rate is an important evaluation indicator for this procedure. As the reporting methods of complications were various and nonstandardized among the included studies, especially the postoperative period, we thus pooled data of complication rates within 30 days and 90 days postoperatively. Moreover, we also analyzed the complication rates using the Clavien grading system. Overall perioperative complication rates within 30 days and 90 days were significantly lower in the RARC group than the ORC group. After grading complications, grade 4 complication rate was significantly lower in the RARC group within 30 days, and grade 3–4 complication rates were significantly lower in the RARC group within 90 days. The results indicates that RARC might be safer compared to ORC, especially in the long term. Of all the included studies, Ng et al. [10] reported their complications using a more standard method with detailed data. Their results showed that RARC was an independent predictor of fewer overall and major complications within 30 days and 90 days postoperatively, and higher
American Society of Anesthesiologists (ASA) score (3–4) as well as longer surgical time were independent predictors of major complications [10]. The lower complication rates in RARC group may be related to lower EBL and minimally invasive approach. Given that patients with muscle invasive bladder cancer are often elderlies with comorbidities, the lower complication rates may suggest that RARC is a better modality selection. Phillips et al. [34] concluded that RARC should be considered for patients over the age of 80 with clinical indications for RC and complication rates were acceptable even in patients with multiple comorbidities as well as those with previous abdominal surgery or pelvic radiation. Knox et al. [24] reported that RARC was superior in patients older than 70 even when compared to a younger cohort undergoing ORC. Several other studies also showed that RARC can be offered as treatment option in selected older patients [35,36].
With regard to oncologic outcomes, like most of the included studies, we used PSM rates and LNY to evaluate efficacy of RARC and ORC. PSM rate of RC are associated with progression to metastatic disease and unfavorable survival in patients with muscle invasive bladder cancer [37,38]. Our study showed that there was no difference between RARC and ORC in terms of overall unspecified PSM rates, urethral/ureteric and soft tissue PSM rates. The overall PSM rates in RARC and ORC groups were 5.7% and 8.8%, respectively, which were comparable with other RARC and ORC series [39,40]. A propensity score matched analysis showed that RARC had a lower soft tissue PSM rate compared to ORC [20]. We should cautiously
draw a conclusion like RARC having equivalent PSM rate compared to ORC because PSM was highly correlated with pathological stage and selection bias did exist in some of the included studies.

Another important indicator of surgical quality of RC is LNY. Although more lymph nodes were yielded in RARC from our meta-analysis, two RCTs showed no significant difference between the two techniques. So we can only draw a conclusion of the noninferiority of robotic approach regarding lymph node dissection. Indeed, LNY in RARC is correlated with various

| Study or Subgroup | RARC | ORC | Mean Difference | Mean Difference |
|-------------------|------|-----|-----------------|-----------------|
|                   | Mean | SD  | Total | Mean | SD  | Total | Weight | IV, Random, 95% CI | Year |
| Sterrett 2007     | 126.3 | 98.8 | 19 | 85 | 25.3 | 33 | 7.0% | 41.30 [-3.39, 86.56] | 2007 |
| Pruthi 2007       | 31.3  | 15   | 20 | 58.8 | 22.5 | 24 | 12.1% | -27.50 [-38.65, -16.35] | 2007 |
| Ng 2010           | 46.2  | 29.9 | 83 | 117.2 | 91.6 | 104 | 11.1% | -71.29 [-89.94, -52.46] | 2010 |
| Martin 2011       | 31.5  | 16.3 | 19 | 74.8 | 34.8 | 14 | 11.0% | -43.39 [-62.95, -23.85] | 2011 |
| Slyn 2012         | 35.7  | 37.5 | 50 | 47.5 | 48.3 | 100 | 11.8% | -12.50 [-26.56, 1.56] | 2012 |
| Sung 2012         | 44.8  | 23.1 | 35 | 106.3 | 89.3 | 104 | 11.1% | -61.59 [-80.29, -42.71] | 2012 |
| Khan 2012         | 33.7  | 21.6 | 48 | 135.2 | 112.9 | 52 | 9.1%  | -101.50 [-132.79, -70.21] | 2012 |
| Kader 2013        | 42.3  | 42.5 | 100 | 98.6 | 63.3 | 100 | 11.7% | -56.39 [-71.24, -41.36] | 2013 |
| Musch 2013        | 35.1  | 17   | 100 | 81 | 62.1 | 42 | 11.1% | -45.90 [-64.97, -26.83] | 2013 |
| Knox 2013         | 27.6  | 36.9 | 58 | 152.2 | 338.3 | 84 | 4.0%  | -124.60 [-157.57, -51.63] | 2013 |

Total (95% CI): -47.39 [-65.13, -29.65].

Heterogeneity: Tau² = 644.17; Chi² = 72.37, df = 9 (P < 0.00001); I² = 88%
Test for overall effect: Z = 5.24 (P < 0.00001)

Fig 8. Forest plots of estimated blood loss.

doi:10.1371/journal.pone.0121032.g008

Fig 9. Forest plots of transfusions. (a) perioperative transfusion; (b) intraoperative transfusion.

doi:10.1371/journal.pone.0121032.g009
factors, like surgeon volumes, institution volumes \[41\] and learning curve \[42\]. The data from International Robotic Cystectomy Consortium (IRCC) showed robot-assisted lymph node dissection can achieve similar LNY to those of open lymph node dissection after RC \[41\]. Davis et al. \[43\] concluded that robot assisted pelvic lymph node dissection yielded of 93% of that of open surgery by using second look open dissection method. In summary, with the three dimensional visualization and flexible instruments, RARC is expected to achieve similar oncologic outcomes to ORC after the learning curve.

The longer OT in the RARC group may due to the initial small surgeon volumes and learning curve impact. With the increasing surgical skills and better team cooperation, the OT of RARC is expected to be diminished in some degree. Our subgroup analysis indirectly suggested that OT difference between ORC and RARC was smaller for robotic cases more than 50. Several included studies reported that OT of RARC decreased when surgeon volumes increased \[7,15,16\]. The longer OT in RARC group can also be attributed to the extra operative steps associated with the trocar placement, docking and undocking of the robot, and conversion to extracorporeal urinary diversion \[23\]. Moreover, RC itself is a time-consuming operation. In the largest comparative study, the mean OT in the RARC group and ORC group were 6.25 hours and 5.95 hours, respectively \[10\]. Small OT gap between RARC and ORC may be not as important as other outcome differences. Besides, the lower complication rates, lower EBL as well as shorter LOS in the RARC group could easily balance the small difference with the OT.

This meta-analysis showed significant less EBL and a lower need for transfusion in the RARC group. The markedly lower blood loss in the RARC group can probably be explained by the effect of the pneumoperitoneum and more precise coagulation of bleeding vessels achieved through three dimensional visual field and flexible instruments \[23,44\]. Learning curve also have effects on the EBL \[15,45\]. Less blood loss may be a valuable finding because EBL and transfusion requirements is correlated with complications \[46–49\].

Learning curve, which has some influences on surgical outcomes, is an essential parameter to evaluate for an emerging technique like RARC. First of all, compared to conventional laparoscopic surgery, robotic assistance greatly reduces the learning curve for minimally invasive
pelvic procedures like RC [50]. Pruthi et al. [45] described the learning curve of RARC and found initial 25 cases did have longer OT and more EBL than latter cases, but no compromises were observed with regard to complications and oncologic parameters like PSM rates and LNY. RARC can be performed safely without compromising operative, postoperative, and short-term pathologic outcomes during the learning curve for surgeons who are experienced in

Fig 11. Subgroup analysis including studies with more than 50 robotic cases. (a) overall complication rates within 30 days; (b) overall complication rates within 90 days; (c) positive surgical margin rates; (d) lymph nodes yields; (e) operative time; (f) estimated blood loss; (g) length of stay.

doi:10.1371/journal.pone.0121032.g011
ORC [51]. However, for younger surgeons who have not received much ORC training, it is imperative to start with easier robotic surgeries. Guru et al. [52] highly recommended mastering robot-assisted radical prostatectomy (RARP) before attempting RARC. IRCC demonstrated an acceptable level of proficiency by the 30th case for proxy measures of RARC quality [53]. This could be a guidance for younger surgeons and their trainers.

Different financial incentives for hospital discharge exist among healthcare systems or countries [23]. The significantly shorter LOS in the RARC group is worth mentioning given that most of the included studies came from USA. Shorter LOS may due to the less invasive approach and lower complication rates. However, neither of the RCTs showed any difference despite RARC group had a trend toward fewer prolonged hospitalizations (LOS greater than 5 days) [11,22]. Whether the lower complication rates and shorter LOS in the RARC group can lead to a potential benefit in quality of life (QOL) is another considerable question. One of the included RCTs reported their QOL outcomes in a different paper, in which QOL was assessed by Functional Assessment of Cancer Therapy–Vanderbilt Cystectomy Index (FACT–VCI) questionnaire preoperatively and then at 3, 6, 9 and 12 months postoperatively [22,54]. The results showed a slightly higher physical well-being score in the RARC group at 6 months, but no difference was observed in other domains [54]. Guru et al [55] reported that patients who had RARC required less opiates postoperatively compared to those who had ORC, although both groups achieved similar pain control. However, another study showed better sexual functions in the ORC group over time [56]. Given that there is still lack of standardization of QOL measures and much of the studies were retrospective or had small sample size, larger RCTs with standard outcomes are needed to characterize QOL difference between RARC and ORC.

Cost analysis between two groups, although was not one of our outcomes, deserves to be discussed because health care cost control is one of the most essential topics in modern era [57].
Smith et al. [58] concluded that RARC was associated with a higher financial cost (+$1,640) than ORC in the perioperative setting. However, they excluded the analysis of hospital medication cost, as well indirect cost of complications. Another study performed a cost-analysis between RARC and ORC using a model, which included both direct and indirect cost of 30-day complications and hospital medications [18]. Interestingly, actual total patient costs revealed a 38% cost advantage favoring RARC due to increased hospitalization costs for ORC and higher complication rates [18]. The cost benefit of RARC was also observed in the largest cohort study [10,59]. Various factors, such as hospital volume, LOS, OT, morbidity, and complexity of urinary diversion, can influence the cost. All we can expect is large RCTs between the two surgical approaches and hope they can effectively assess whether a cost benefit does exist.

Although RARC has its advantages, ORC is still an important and indispensable procedure for urologist to learn. Even in USA, which is equipped with the largest number of robotic surgical system in the world, RARC is only a small portion of total RC cases. Data from the Nationwide Inpatient Sample in 2009 to 2011 showed that RARC accounted for about 12.6% of all RC cases [60]. ORC will still be the gold standard for muscle invasive bladder cancer in the short and medium term. Like all other surgeries, ORC training can help younger surgeons to be familiar with anatomic structure directly. Besides, surgical skills and experience from open cases are essential because all surgeons have to be prepared for intraoperative conversion during any minimally invasive procedures.

There are certain limitations to be considered in the present review and meta-analysis. The main limitation is that most of the included studies were observational studies except two RCTs, both of which used inappropriate randomization method and had limited number of patients (40 and 41, respectively) [11,22]. Overall, studies included in the analysis had small patient cohorts. Ten out of nineteen studies had less than 100 patients. Secondly, some of the included studies probably had the risk of selection bias which might limit the power of this meta-analysis. However, our study has relatively large sample size and standard data extraction and analysis. Our conclusions thus could provide guidance for both urologists and healthcare policy makers.

Conclusions

Nineteen studies assessing RARC versus ORC were included for this meta-analysis. The results indicated that RARC may be associated with lower overall perioperative complication rates within 30 days and 90 days, lower grade 3 perioperative complication rate within 30 days, lower grade 3 and 4 perioperative complication rates within 90 days, more LNY, longer OT, less EBL, lower need for transfusion and shorter LOS. Conclusively, RARC appears to be a safer, less invasive procedure with same efficacy when compared with ORC. In spite of our rigorous methodological review, limitations of the included studies imposed restrictions on us to draw definite conclusions. Large cohort studies and well-designed RCTs with longer follow-up are needed to confirm and update the findings of this analysis.

Supporting Information

S1 PRISMA Checklist. PRISMA Checklist. (DOC)

Author Contributions

Conceived and designed the experiments: ZS LX XW TX. Performed the experiments: LX XW TX. Analyzed the data: LX XW TX. Contributed reagents/materials/analysis tools: LX XW TX.
Xiaohua Z. ZZ LQ Xiang Z. CF MZ SZ ZS. Wrote the paper: LX XW TX. Proofreading: XW TX Xiaohua Z. ZZ LQ Xiang Z. CF MZ SZ ZS.

References

1. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, et al. (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59: 1009–1018. doi: 10.1016/j.eururo.2011.03.023 PMID: 21454009

2. Lawrentschuk N, Colombo R, Hakenberg OW, Lerner SP, Mansson W, et al. (2010) Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol 57: 983–1001. doi: 10.1016/j.eururo.2010.02.024 PMID: 20227172

3. Menon M, Hemal AK, Tewari A, Shrivastava A, Shoma AM, et al. (2003) Nerve-sparing robot-assisted radical cystoprostatectomy and urinary diversion. BJU Int 92: 232–236. PMID: 12887473

4. Snow-Lisy DC, Campbell SC, Gill IS, Hernandez AV, Fergany A, et al. (2014) Robotic and Laparoscopic Radical Cystectomy for Bladder Cancer: Long-term Oncologic Outcomes. Eur Urol 65: 193–200. doi: 10.1016/j.eururo.2013.08.021 PMID: 24018019

5. Khan MS, Elhage O, Challacombe B, Murphy D, Coker B, et al. (2013) Long-term outcomes of robot-assisted radical cystectomy for bladder cancer. Eur Urol 64: 219–224. doi: 10.1016/j.eururo.2013.01.006 PMID: 23395594

6. Galich A, Sterrett S, Nazemi T, Pohlman G, Smith L, et al. (2006) Comparative analysis of early perioperative outcomes following radical cystectomy by either the robotic or open method. JSLS 10: 145–150. PMID: 16882409

7. Pruthi RS, Wallen EM (2007) Robotic assisted laparoscopic radical cystoprostatectomy: operative and pathological outcomes. J Urol 178: 814–818. PMID: 17631334

8. Sterrett S, Mammen T, Nazemi T, Galich A, Peters G, et al. (2007) Major urological oncological surgeries can be performed using minimally invasive robotic or laparoscopic methods with similar early perioperative outcomes compared to conventional open methods. World J Urol 25: 193–198. PMID: 17171562

9. Wang GJ, Barocas DA, Raman JD, Scherr DS (2008) Robotic vs open radical cystectomy: prospective comparison of perioperative outcomes and pathological measures of early oncological efficacy. BJU Int 101: 89–93. PMID: 17888044

10. Ng CK, Kauffmann EC, Lee MM, Otto BJ, Portnoff A, et al. (2010) A comparison of postoperative complications in open versus robotic cystectomy. Eur Urol 57: 274–281. doi: 10.1016/j.eururo.2009.06.001 PMID: 19560255

11. Nix J, Smith A, Kurpad R, Nielsen ME, Wallen EM, et al. (2010) Prospective randomized controlled trial of robotic versus open radical cystectomy for bladder cancer: perioperative and pathologic results. Eur Urol 57: 196–201. doi: 10.1016/j.eururo.2009.10.024 PMID: 19853987

12. Richards KA, Hemal AK, Kader AK, Pettus JA (2010) Robot assisted laparoscopic pelvic lymphadectomy at the time of radical cystectomy rivals that of open surgery: single institution report. Urology 76: 1400–1404. doi: 10.1016/j.urology.2010.01.019 PMID: 20350755

13. Gondo T, Yoshikoa K, Nakagamia Y, Okubo H, Hashimotoa T, et al. (2012) Robotic versus open radical cystectomy: prospective comparison of perioperative and pathological outcomes in Japan. Jpn J Clin Oncol 42: 625–631. doi: 10.1093/jjc/jhs062 PMID: 22581913

14. Khan MS, Challacombe B, Elhage O, Rimghton P, Coker B, et al. (2012) A dual-centre, cohort comparison of open, laparoscopic and robotic-assisted radical cystectomy. Int J Clin Pract 66: 656–662. doi: 10.1111/j.1742-1241.2011.02888.x PMID: 22507234

15. Styn NR, Montgomery JS, Wood DP, Hafez KS, Lee CT, et al. (2012) Matched comparison of robotic-assisted and open radical cystectomy. Urology 79: 1303–1308. doi: 10.1016/j.urology.2012.01.055 PMID: 22516354

16. Sung HH, Ahn JS, Seo SI, Jeon SS, Choi HY, et al. (2012) A comparison of early complications between open and robot-assisted radical cystectomy. J Endourol 26: 670–675. doi: 10.1089/end.2011.0372 PMID: 22011001

17. Nepple KG, Strope SA, Grubb RL 3rd, Kibel AS (2013) Early oncologic outcomes of robotic vs open radical cystectomy for urothelial cancer. Urol Oncol 31: 894–898. doi: 10.1016/j.urolonc.2011.06.009 PMID: 21803615

18. Martin AD, Nunez RN, Castle EP (2011) Robot-assisted radical cystectomy versus open radical cystectomy: a complete cost analysis. Urology 77: 621–625. doi: 10.1016/j.urology.2010.07.502 PMID: 21129900
19. Abaza R, Dangle PP, Gong MC, Bahnson RR, Pohar KS (2012) Quality of lymphadenectomy is equivalent with robotic and open cystectomy using an extended template. J Urol 187: 1200–1204. doi: 10.1016/j.juro.2011.11.092 PMID: 22341295

20. Ahdoot M, Almario L, Araya H, Busch J, Conti S, et al. (2014) Oncologic outcomes between open and robotic-assisted radical cystectomy: a propensity score matched analysis. World J Urol. doi: 10.1007/s00345-014-1242-4 PMID: 24469858

21. Li K, Lin T, Fan X, Xu K, Bi L, et al. (2013) Systematic review and meta-analysis of comparative studies reporting early outcomes after robot-assisted radical cystectomy versus open radical cystectomy. Cancer Treat Rev 39: 551–560. doi: 10.1016/j.ctrv.2012.11.007 PMID: 23273846

22. Parekh DJ, Messer J, FitzGerald J, Ercole B, Svatek R (2013) Perioperative outcomes and oncologic efficacy from a pilot prospective randomized clinical trial of open versus robotic assisted radical cystectomy. J Urol 189: 474–479. doi: 10.1016/j.juro.2012.09.077 PMID: 23017529

23. Musch M, Janowski M, Stoves A, Roggenbuck U, Boergers A, et al. (2014) Comparison of early postoperative morbidity after robot-assisted and open radical cystectomy: results of a prospective observational study. BJU Int. 113:458–467. doi:10.1111/bju.12374 PMID: 24053793

24. Knox ML, El-Galley R, Busby JE (2013) Robotic versus open radical cystectomy: identification of patients who benefit from the robotic approach. J Endourol 27: 40–44. doi:10.1089/end.2012.0168 PMID: 22788707

25. Kader AK, Richards KA, Krane LS, Pettus JA, Smith JJ, et al. (2013) Robot-assisted laparoscopic vs open radical cystectomy: comparison of complications and perioperative oncological outcomes in 200 patients. BJU Int 112: E290–294. doi:10.1111/bju.12167 PMID: 23815802

26. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097. doi:10.1371/journal.pmed.1000097 PMID: 19621072

27. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, et al. Levels of evidence and grades of recommendation. Oxford Centre for Evidence-based Medicine. Available: http://www.cebm.net/index.aspx?o=1025. Accessed 10 April 2014.

28. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Ottawa Hospital Research Institute. Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 10 April 2014.

29. Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5: 13. PMID:15840177

30. Hadziyazicaria P, Stein JP, Cai J, Miranda G (2009) The impact of positive soft tissue surgical margins following radical cystectomy for high-grade, invasive bladder cancer. World J Urol 27: 33–38. doi: 10.1007/s00345-008-0345-1 PMID: 19020884
39. Hellenthal NJ, Hussain A, Andrews PE, Carpentier P, Castle E, et al. (2010) Surgical margin status after robot assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J Urol 184: 87–91. doi: 10.1016/j.juro.2010.03.037 PMID: 20478596

40. Novara G, Svatek RS, Karkiewicz PI, Skinner E, Ficarra V, et al. (2010) Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol 183: 2165–2170. doi: 10.1016/j.juro.2010.02.021 PMID: 20399473

41. Marshall SJ, Hayn MH, Stegemann AP, Agarwal PK, Badani KK, et al. (2013) Impact of surgeon and volume on extended lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium (IRCC). BJU Int 111: 1075–1080. doi: 10.1111/j.1464-410X.2012.11583.x PMID: 23442001

42. Hellenthal NJ, Hussain A, Andrews PE, Carpentier P, Castle E, et al. (2011) Lymphadenectomy at the time of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. BJU Int 107: 642–646. doi: 10.1111/j.1464-410X.2010.09473.x PMID: 20575975

43. Davis JW, Gaston K, Anderson R, Dinney CP, Grossman HB, et al. (2011) Robot assisted extended lymphadenectomy at radical cystectomy: lymph node yield compared with second look open dissection. J Urol 185: 79–83. doi: 10.1016/j.juro.2010.09.031 PMID: 21074799

44. Azzouni F (2013) Current status of minimally invasive radical cystectomy: an outcome-based comparison. Expert Rev Anticancer Ther 13: 681–695. doi: 10.1586/era.13.39 PMID: 23773103

45. Pruthi RS, Smith A, Wallen EM (2008) Evaluating the learning curve for robot-assisted laparoscopic radical cystectomy. J Endourol 22: 2469–2474. doi: 10.1089/end.2008.0320 PMID: 19046088

46. Johar RS, Hayn MH, Stegemann AP, Ahmed K, Agarwal P, et al. (2013) Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol 64: 52–57. doi: 10.1016/j.euro.2013.01.010 PMID: 23380164

47. Bostrom PJ, Koss J, Laato M, Nurmi M (2009) Risk factors for mortality and morbidity related to radical cystectomy. BJU Int 103: 191–196. doi: 10.1111/j.1464-410X.2008.07889.x PMID: 18671789

48. Chang SS, Cookson MS, Baumgartner RG, Wells N, Smith JA Jr. (2002) Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J Urol 167: 2012–2016. PMID: 11956429

49. Kaufman EC, Ng CK, Lee MM, Otto BJ, Portnoff A, et al. (2010) Critical analysis of complications after robotic-assisted radical cystectomy with identification of preoperative and operative risk factors. BJU Int 105: 520–527. doi: 10.1111/j.1464-410X.2009.08843.x PMID: 19735257

50. Abraham JB, Young JL, Box GN, Lee HJ, Deane LA, et al. (2007) Comparative analysis of laparoscopic and robot-assisted radical cystectomy with ileal conduit urinary diversion. J Endourol 21: 1473–1480. doi: 10.1089/end.2007.0095 PMID: 18186686

51. Richards KA, Kader K, Pettus JA, Smith JJ, Hemal AK (2011) Does initial learning curve compromise outcomes for robot-assisted radical cystectomy? A critical evaluation of the first 60 cases while establishing a robotics program. J Endourol 25: 1553–1558. doi: 10.1089/end.2010.0630 PMID: 21834666

52. Guru KA, Perlmutter AE, Butt ZM, Piaccete P, Wilding GE, et al. (2009) The learning curve for robot-assisted radical cystectomy. JSLS 13: 509–514. doi: 10.4293/108680809X12589998404128 PMID: 20042129

53. Hayn MH, Hussain A, Mansour AM, Andrews PE, Carpentier P, et al. (2010) The learning curve of robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol 58: 197–202. doi: 10.1111/j.1464-410X.2010.04.024 PMID: 20434830

54. Messer JC, Punnen S, Fitzgerald J, Svatek R, Parekh DJ (2014) Health-related quality of life from a prospective randomised clinical trial of robot-assisted laparoscopic vs open radical cystectomy. BJU Int 114:896–902. doi: 10.1111/bju.12818 PMID: 24862633

55. Guru KA, Wilding GE, Piaccete P, Thompson J, Deng W, et al. (2007) Robot-assisted radical cystectomy versus open radical cystectomy: assessment of postoperative pain. Can J Urol 14: 3753–3756. doi: 18163928 PMID: 18163928

56. Aboumohamed AA, Raza SJ, Al-Daghmin A, Tallman C, Creighton T, et al. (2014) Health-related quality of life outcomes after robot-assisted and open radical cystectomy using a validated bladder-specific instrument: a multi-institutional study. Urology 83: 1300–1308. doi: 10.1016/j.urology.2014.02.024 PMID: 24746661

57. Mmeje CO, Martin AD, Nunez-Nateras R, Parker AS, Thiel DD, et al. (2013) Cost analysis of open radical cystectomy versus robot-assisted radical cystectomy. Curr Urol Rep 14: 26–31. doi: 10.1007/s11934-012-0292-7 PMID: 23184624

58. Smith A, Kuprad L, Lai A, Nielsen M, Wallen EM, et al. (2010) Cost analysis of robotic versus open radical cystectomy for bladder cancer. J Urol 183: 505–509. doi: 10.1016/j.juro.2009.09.081 PMID: 20006882
59. Lee R, Ng CK, Shariat SF, Borkina A, Guimento R, et al. (2011) The economics of robotic cystectomy: cost comparison of open versus robotic cystectomy. BJU Int 108: 1886–1892. doi: 10.1111/j.1464-410X.2011.10114.x PMID: 21501370

60. Monn MF, Cary KC, Kaimakliotis HZ, Flack CK, Koch MO (2014) National trends in the utilization of robotic-assisted radical cystectomy: An analysis using the Nationwide Inpatient Sample. Urol Oncol 32:785–90. doi: 10.1016/j.urolonc.2014.04.007 PMID: 24863014